A comprehensive view of FDA Drug / Device Reviews. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA accepts Sanofi's supplementary application for priority review of Dupixent as a potential treatment for moderate to severe chronic obstructive pulmonary disease with type 2 inflammation; a decision is expected by June 27, 2024

FDA grants priority review to Regeneron's BLA for linvoseltamab as a treatment for multiple myeloma, decision date is set for August 22, 2024; European medicines agency accepted the drug for review earlier this month

FDA accepts Bristol Myers’ supplemental new drug application for Krazati adagrasib combined with Cetuximab for priority review; the targeted treatment is meant for patients with previously treated KRASG12C-mutated colorectal cancer

Bristol Myers announces acceptance of US and EU regulatory filings for neoadjuvant opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant opdivo in resectable non-small cell lung cancer

GSK’s RSV vaccine, AREXVY, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count